Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF March 10, 2017 | Archived Issues

Meetings and Events


Grand Rounds


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - March 2017 (PDF)  


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue.

Submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

With Grant, Biological Pacemakers Closer to Reality

Eugenio Cingolani, MD

With a new $3 million grant from the National Institutes of Health, Cedars-Sinai Heart Institute investigators are moving closer to their goal of developing a biological pacemaker that can treat patients afflicted with slow heartbeats. The novel, minimally invasive gene therapy turns patients’ normal heart cells into pacemaker cells that regulate heart function — potentially replacing electronic pacemakers one day.

"Although implantable pacemakers have helped save millions of lives since they were invented in the 1960s, biological pacemakers could result in a healthier alternative," said Eugenio Cingolani, MD, the principal investigator in the project and the director of the Cedars-Sinai Heart Institute’s Cardiogenetics Program. "Devices can malfunction or become infected, while biological pacemakers avoid such complications."

Specialized pacemaker cells are found naturally in the heart. This tiny cluster of cells generates electrical activity that spreads throughout the heart in an orderly pattern to create rhythmic muscle contractions — heartbeats. But if pacemaker cells go awry, the heartbeats slow down, causing fainting or even sudden death. Patients with slow heartbeats who are healthy enough to undergo surgery often look to an electronic pacemaker as their only treatment option.

As a practicing cardiac electrophysiologist, Cingolani has first-hand experience with heart rhythm devices and their limitations. He and his team of investigators are working toward delivering a gene directly to a patient’s heart during a minimally invasive catheter-based procedure. The gene would then convert normal heart cells into pacemaker cells that keep the heart beating steadily.

"In 2012, our team was the first to show that we can inject a single gene, called Tbx18, into a regular heart cell and turn that cell into a specialized pacemaker cell," said Eduardo Marbán, MD, PhD, co-principal investigator on the project and director of the Cedars-Sinai Heart Institute. "This new funding will help us complete long-term safety and efficacy data using clinical-grade gene delivery systems, hopefully leading to a clinical trial in which we can test the therapy in selected patients."

If the upcoming safety studies are successful, Cingolani says the biological pacemaker could be tested in patients within five years.